BNP Paribas Financial Markets’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-1,322
Closed -$707 5665
2024
Q4
$707 Buy
+1,322
New +$921 ﹤0.01% 5128
2022
Q4
Sell
-129
Closed -$858 4769
2022
Q3
$858 Buy
+129
New +$794 ﹤0.01% 4449
2020
Q3
Sell
-1,546
Closed -$15.7K 4307
2020
Q2
$15.7K Sell
1,546
-4,571
-75% -$42K ﹤0.01% 3502
2020
Q1
$49.7K Buy
6,117
+4,373
+251% +$37.9K ﹤0.01% 3543
2019
Q4
$15.1K Sell
1,744
-186
-10% -$1.04K ﹤0.01% 4065
2019
Q3
$11.9K Buy
1,930
+611
+46% +$4.94K ﹤0.01% 4115
2019
Q2
$21.9K Sell
1,319
-1,193
-47% -$20.7K ﹤0.01% 3865
2019
Q1
$42K Buy
2,512
+2,351
+1,460% +$33.9K ﹤0.01% 3605
2018
Q4
$1.84K Sell
161
-137
-46% -$2.77K ﹤0.01% 3818
2018
Q3
$11.9K Hold
298
﹤0.01% 3652
2018
Q2
$8.41K Buy
+298
New +$6.61K ﹤0.01% 3862

BNP Paribas Financial Markets's MRNS Position: Q1 2025 in Review

BNP Paribas Financial Markets sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 1,322 shares — an estimated $707 sold.

BNP Paribas Financial Markets first reported a position in MRNS in Q2 2018 and held it in 11 quarters. The position peaked at $49.7K in Q1 2020. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.

  • BNP Paribas Financial Markets reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,322 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $707.
  • BNP Paribas Financial Markets first reported a position in Marinus Pharmaceuticals, Inc in Q2 2018 and held it in 11 quarters.
  • BNP Paribas Financial Markets's Marinus Pharmaceuticals, Inc position peaked at $49.7K in Q1 2020.
  • 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2025, filed 14 May 2025.